FDA AdComm meeting over Novartis' Serelaxin

An FDA advisory committee is meeting to discuss whether to approve Novartis' (NVS) Serelaxin treatment for acute heart failure.

On Tuesday, FDA staff recommended that the agency not approve Serelaxin.

You can watch the AdComm here.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs